Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | RARA | P10276 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliquidone SCHEMBL15669239 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL29465034 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL676846 | 0.99 | LMNA (0.98) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL8216020 | 0.93 | LMNA (0.87) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL28086518 | 0.91 | LMNA (0.82) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL21824303 | 0.89 | CYP2C9 (0.79) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL27714721 | 0.88 | CYP2C9 (0.78) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL10281162 | 0.86 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL11929012 | 0.86 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL25866045 | 0.86 | CYP3A4 (0.75) | LMNACYP3A4CYP2C9ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10493 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4714927-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A SULFINATE AND A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714925-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714928-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A HETEROCYCLIC COMPOUND COMPRISING AT LEAST ONE N-N SINGLE BOND | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714926-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4691496-A1 | PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4680240-A1 | METHOD OF TREATING DISORDERS WITH SURF1 MALFUNCTION | Cure Mito Foundation (US) | 2026-01-21 | — | — | EP | claimed |
| US-5859037-A | MIXTURE SYNERGISTIC FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS IN HUMANS, WHICH ALSO IMPROVES GLYCEMIC CONTROL | WARNER-LAMBERT COMPANY (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998056378-A1 | NOVEL NIDDM REGIMEN | NOVO NORDISK A/S (DK) | 1998-12-17 | — | — | WO | claimed |
| CN-1195531-A | Drug for curing diabetes and its preparing method | YAO YUANLIN (CN) | 1998-10-14 | — | — | CN | claimed |
| WO-1998036755-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER LAMBERT COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| WO-1997041857-A1 | COMPOSITION COMPRISING A KATP CHANNEL INHIBITOR FOR USE IN THE TREATMENT OF HEMORRHAGIC SHOCK | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 1997-11-13 | — | — | WO | claimed |
| CN-1156403-A | Highly active sulphonyl urea preparations exhibiting rapid or controlled release of the active substance, and method of producing them | BRITISH TECHNOLOGY GROUP CO LT (GB) | 1997-08-06 | — | — | CN | claimed |
| EP-0128483-B1 | GALENIC FORMS OF ORAL ANTIDIABETICS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1990-09-12 | — | — | EP | claimed |
| EP-0128482-B1 | GALENIC FORMS OF ORAL ANTIDIABETICS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1990-01-31 | — | — | EP | claimed |
| US-4708868-A | Oral anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-11-24 | — | — | US | claimed |
| US-4696815-A | Anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | claimed |